Efficacy and safety of Helicobacter pylori eradication therapy with Vonoprazan, reduced dosage of amoxicillin, and clarithromycin for patients on dialysis for renal failure

Soichiro Sue0 个研究点目标入组 23 人开始时间: 2020年12月11日最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•Patients infected with Helicobacter pylori. Positive patients by Urea breath test, stool Helicobacter pylori antigen test, anti-Helicobacter pylori antibody test (blood), Helicobacter pylori culture are treated with infected.
•Patients diagnosed as chronic gastritis, gastroduodenal ulcer, MALT lymphoma, idiopathic thrombocytopenic purpura, or after endoscopic treatment of early gastric cancer, and performed upper gastrointestinal endoscopy within a year.
•Hemodialysis patients for end-stage renal failure.
•Patients who give a written informed consent.

•Patients who have Helicobacter pylori eradication history. Pregnancy or lactation. Patients using stazanavir, rilpivirine, pimozide, ergotamine, suvorexant, lomitapide mesylate, tadalafil, ticagrelor, ibrutinib, asuna previr, ivavradine, venetoclax, lurasidone hydrochloride, anamorelin hydrochloride, finerenone, isavuconazonium sulfate, or colchicine. Patients who are disqualified for the study by physicians.

发起方

Soichiro Sue